

Freedom of Information Act Disclosure log - Reply Extract

File reference	W21FOI088
Key words	Patients Treated with Anti-VEGF Treatments
Date of release	28/05/2021
Attachments	No

You asked

I am analysing the usage of anti-VEFG treatments for eye conditions. I would greatly appreciate if you could answer the below questions:

1. For the 4-month period from January to April 2021, how many patients has your trust treated with the following anti-VEGF treatments:

- **Aflibercept** = See notes below*
- **Bevacizumab** = See notes below*
- **Brolucizumab** = 0
- **Dexamethasone** = See notes below*
- **Fluocinolone acetonide** = See notes below*
- **Ranibizumab** = See notes below*

*The Trust does not hold this information within searchable records. To assist you, the Trust publishes quarterly data stating the number of each item issued. It is published here: <https://www.plymouthhospitals.nhs.uk/pharmacy>. The last quarter is due for publication shortly. Brolucizumab is not prescribed within the organisation and not included on the published list.

Please note for future requests, the Trust would refuse any patient number/drug requests for periods different to our published date range. This is because it significantly increases the risk of personal information being disclosed now or in the future.

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Fluocinolone acetonide**
- **Ranibizumab**

The Trust does not hold this information within searchable records.

3. Within your trust, how many intra-vitreous injections/implants of each of the following treatments have been used (for any eye condition) in the four-month period from January to April 2021:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone
- Ranibizumab

The Trust does not hold this information within searchable records.

4. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from January to April 2021 for each of the following conditions:

Diabetic Macular Oedema (DMO)

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

The Trust does not hold this information within searchable records.

Legal notes

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it does not hold the information requested; except in relation to Brolucizumab because it is not prescribed and therefore all answers are nil. Advice and assistance has been offered within the reply.

Attachments included: No